MARKET

AGRX

AGRX

Agile
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.230
0.000
0.00%
After Hours: 2.300 +0.07 +3.14% 17:37 03/05 EST
OPEN
2.280
PREV CLOSE
2.230
HIGH
2.290
LOW
2.000
VOLUME
1.89M
TURNOVER
--
52 WEEK HIGH
3.890
52 WEEK LOW
1.350
MARKET CAP
195.41M
P/E (TTM)
-3.6793
1D
5D
1M
3M
1Y
5Y
Agile Therapeutics to Present at Upcoming March Investor Conferences
PRINCETON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at two investor conferences in March. H.C. Wainwri...
GlobeNewswire · 2d ago
Agile Therapeutics (AGRX) Gets a Buy Rating from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Agile Therapeutics (AGRX), with a price target of $8.00. The
SmarterAnalyst · 4d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agile Therapeutics (AGRX) and Athenex (ATNX)
SmarterAnalyst · 5d ago
DJ Agile Therapeutics, Inc. CEO Alfred Altomari on Q4 2020 Results -- Earnings Call Transcript >AGRX
Dow Jones · 5d ago
Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 13.04% and -25.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
BRIEF-Agile Therapeutics Reports Q4 Loss Per Share Of $0.20
reuters.com · 5d ago
10-K: AGILE THERAPEUTICS INC
Edgar Online - (EDG = 10Q, 10K) · 5d ago
Agile Therapeutics 4Q Loss $17.6M >AGRX
Agile Therapeutics 4Q Loss $17.6M >AGRX
Dow Jones · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGRX. Analyze the recent business situations of Agile through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGRX stock price target is 8.25 with a high estimate of 10.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 128
Institutional Holdings: 49.43M
% Owned: 56.41%
Shares Outstanding: 87.63M
TypeInstitutionsShares
Increased
28
2.24M
New
19
586.51K
Decreased
17
1.20M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Chief Executive Officer/Director
Alfred Altomari
Chief Financial Officer/Senior Vice President
Dennis Reilly
Senior Vice President/General Counsel/Secretary
Geoffrey Gilmore
Senior Vice President
Robert Conway
Other
Paul Korner
Lead Director/Independent Director
Seth Fischer
Director
Sandra Carson
Independent Director
Sharon Barbari
Independent Director
John Hubbard
Independent Director
Ajit Shetty
Independent Director
James Tursi
No Data
  • All
  • Financials
  • Insiders
More
About AGRX
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Webull offers kinds of Agile Therapeutics Inc stock information, including NASDAQ:AGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGRX stock methods without spending real money on the virtual paper trading platform.